Market Definition
Hepatocellular Carcinoma (HCC) is a liver malignancy that emerges in liver cells and is the sixth most common cancer worldwide. It is the third most cause of cancer-related deaths globally, with prominent risk factors, including excessive alcohol consumption, HBV (Hepatitis B Virus) & HCV (Hepatitis C Virus) infections, and other lifestyle disorders.
Market Insights
The Global Hepatocellular Carcinoma (HCC) Market is projected to grow at a CAGR of around 10.20% during the forecast period, i.e., 2022-27. The growth of the market is driven primarily by the increasing instances of liver cancer & rising mortality rates owing to severe lifestyle changes and increasing obesity on account of poor eating habits, coupled with significant investments in research activities associated with the development of advanced therapeutics for HCC.
| Report Coverage | Details |
|---|---|
| Study Period | Historical Data: 2017-20 |
| Base Year: 2021 | |
| Forecast Period: 2022-27 | |
| CAGR | 10.20% |
| Regions Covered | North America: The US, Canada, Mexico |
| Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe | |
| Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific | |
| South America: Brazil, Rest of Latin America | |
| Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa | |
| Key Companies Profiled |
Amgen Inc., AstraZeneca plc, Bayer AG, BeiGene, Bristol Myers Squibb, Eisai Co., Ltd., Merck & Co., Inc., Novartis International AG, Pfizer Inc. |
| Unit Denominations | USD Million/Billion |
Moreover, the rapidly surging clinical trials for HCC drugs & medications by the leading biotech & pharma companies are further creating lucrative prospects for the global market through 2027. FDA, PMDA, & EMA, among other regulatory agencies worldwide, are offering significant incentives to biopharma companies for developing orphan drugs for rare diseases while also providing fast drug approvals. For instance:
With the FDA approval of Avastin (bevacizumab) and Tecentriq (atezolizumab) as the first-line HCC treatment, healthcare R&D has been focusing extensively on developing more effective and affordable combination therapies.
Combinations of PD- 1 or PDL- 1 with multikinase inhibitors, anti-VEGF drugs, or CTLA- 4 inhibitors are already well represented in late-stage HCC. As a result, the rising cases of liver cancer worldwide are creating numerous opportunities for these medications, which, in turn, would expand the global market in the years to come.
However, adverse effects like skin & gastrointestinal disorders, fatigue, hair loss, etc., in many patients suffering from HCC due to high drug dosage, coupled with the unavailability of HCC diagnoses & treatments in rural areas, are a few aspects projected to hinder the growth of the Global Hepatocellular Carcinoma (HCC) Market through 2027.
-Market.jpg)
Market Segmentation
Based on Treatment:
Of all treatments, targeted therapy drugs like Sorafenib & Lenvatinib (kinase inhibitors) led the Global Hepatocellular Carcinoma (HCC) Market in previous years. For many years, they have been the SOC (standard of care) treatment of patients with advanced HCC. Sorafenib is oral bi-aryl urea that inhibits multiple cell surface & downstream kinases involved in tumor progression. Phase 3 randomized placebo-controlled trials conducted across regions like the Americas, Asia, & Europe made Sorafenib a preferred systematic therapy for advanced HCC. It was due to improved OS (overall success) rates in patients, coupled with mild to moderate severity of toxicities, such as hand-foot skin reactions, fatigue, & diarrhea.
However, in May 2020, FDA approved the combination of Avastin (bevacizumab) & Tecentriq (atezolizumab) as the first-line treatment for patients suffering from metastatic or unresectable hepatocellular carcinoma. The combination therapy, i.e., only for those with no history of any systemic therapy, showed enhanced efficacy & safety compared to kinase inhibitors and is projected to dominate the Global Hepatocellular Carcinoma (HCC) Market throughout 2027.
Based on Diagnosis:
Of all HCC diagnoses, blood tests are the most commonly used laboratory tests owing to their accuracy & cost-efficiency. AFP blood tests help identify the treatment, and LFTs, with relatively higher demand than AFP, provide precise information on the liver condition. These tests are considered ideal for screening patients with a significant risk of hepatocellular carcinoma, specifying the disease stage, determining appropriate treatment options, & assessing if there's any response from the disease to the prescribed treatment.
However, rigorous research is being conducted extensively on developing more accurate, efficient, & cost-effective HCC diagnoses. The study areas include the use of receptors & growth factors, enzymes & isoenzymes biomarkers, & molecular markers for the liver cancer diagnoses, portraying promising potential in the nearer future.
On the other hand, after lab tests, imaging diagnoses like CT scans, MRI, hepatic angiography, laparoscopy, etc., help confirm the tumor presence in patients. These tests aid healthcare professionals in the better evaluation of results generated by lab & genetic tests and know the nature & extent of the tumor. One of the most prominent demand barriers for imaging tests is the radiation exposure that may result in severe effects on account of fluorescent & radioactive materials used for image formation.
Nevertheless, with rapid technological advancements, imaging tests are becoming more accurate, safe, efficient, & cost-effective, which projects their significantly surging demand for hepatocellular carcinoma diagnosis over the coming years.
Regional Landscape
Geographically, the Global Hepatocellular Carcinoma (HCC) Market expands across:
Of all regions globally, North America holds a significant share in the Hepatocellular Carcinoma (HCC) Market. It attributes to the well-established healthcare facilities, excellent policies for healthcare insurance reimbursement, the extensive presence of leading biopharma companies & various strategic initiatives by them, the rising geriatric population, and the early adoption of advanced diagnosis & treatments for cancer, including HCC, across the region.
The US holds the major share in the regional market for hepatocellular carcinoma due to rapid technological advancements in drug development, massive R&D investments in developing more effective treatments for HCC, and the easily & extensively available cancer therapeutic drugs in the country.
On the other hand, Asia-Pacific is projected to record the highest market growth rate through 2027. It owes to the mounting prevalence of HBV & HCV, aging populations, and a significant rise in alcohol consumption. Moreover, governments of regional countries are taking various initiatives toward making people aware of the importance & availability of early detection of these diseases. In addition, there is a burgeoning adoption of more effective & accurate diagnostic procedures for HCC, especially in countries like India & China, i.e., another crucial aspect driving the regional market.
Besides, the reducing prices of diagnostics solutions and notable developments in the healthcare infrastructure across the region shall further propel the overall market growth over the coming years. Across Asia-Pacific, China is observing a significantly growing medical tourism sector, coupled with massive funding by the leading biotech & pharma companies in the R&D of cost-effective treatments for HCC.
Key Market Driver: Substantial R&D Investments by Leading Pharma & Biotech Companies Worldwide
The key companies in the biotechnology & pharmaceutical ecosystem are massively investing in R&D activities associated with discovering & implementing more efficient & accurate diagnoses & treatments for hepatocellular cancer. As a result of the rising patient pool of HCC, there's a burgeoning demand for oncology drugs, coupled with increasing strategic collaborations to expand the product portfolio, which, in turn, would drive the Global Hepatocellular Carcinoma (HCC) Market during 2022-27.
Key Questions Answered in the Market Research Report:
Frequently Asked Questions
A. The Global Hepatocellular Carcinoma (HCC) Market is projected to grow at a CAGR of around 10.20% during 2022-27.
A. Growing investments by the leading biopharma companies in developing more advanced & effective HCC diagnosis & treatment entwined with increasing healthcare expenditure by governments of different countries worldwide are the prominent factors projected to drive the Global Hepatocellular Carcinoma (HCC) Market through 2027. On the other hand, severe side effects in HCC patients due to high dosage of drugs might hamper the market growth in the coming years.
A. Targeted therapy would generate remunerative opportunities for the leading players operating in the Global Hepatocellular Carcinoma (HCC) Market over the forecast years.
_Market-_Segmentation.png)